Green shoots in US-India co-operation on drugs quality
This article was originally published in Scrip
The US FDA and India's Central Drugs Standard Control Organization's (CDSCO) collaborative workshop series, the first of which on effective quality systems began in Hyderabad on 5 May, highlighted the FDA's efforts to engage in transparent discussions with industry and regulators to ensure and strengthen the quality, safety, efficacy and integrity of drugs exported to the US.
You may also be interested in...
Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.